Evaluation of (111)In labeled somatostatin analogs for targeted therapy of somatostatin receptor positive tumors.
Bernhardt
P
P
Department of Radiation Physics, Göteborg University, Sahlgrenska University Hospita, Sweden. peter.bernhardt@radfys.quse
Ahlman
H
H
Nilsson
O
O
Benjegård
S A
SA
Forssell-Aronsson
E
E
D018288:Carcinoma, Small Cell / Q000378:metabolism / Q000532:radiotherapy*; D002470:Cell Survival / Q000528:radiation effects; D006801:Humans; D007205:Indium Radioisotopes / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004369:Pentetic Acid / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D017481:Receptors, Somatostatin / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use; D014018:Tissue Distribution; D014407:Tumor Cells, Cultured / Q000378:metabolism / Q000528:radiation effects
D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; C071632:SDZ 215-811; D013004:Somatostatin; D004369:Pentetic Acid; D015282:Octreotide